PASSAGE BIO INC (PASG) Stock Price & Overview
NASDAQ:PASG • US7027122099
Current stock price
The current stock price of PASG is 11.44 USD. Today PASG is up by 5.34%. In the past month the price increased by 42.15%. In the past year, price increased by 64.55%.
PASG Key Statistics
- Market Cap
- 36.722M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -14.35
- Dividend Yield
- N/A
PASG Stock Performance
PASG Stock Chart
PASG Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PASG. When comparing the yearly performance of all stocks, PASG is one of the better performing stocks in the market, outperforming 77.9% of all stocks.
PASG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PASG. While PASG seems to be doing ok healthwise, there are quite some concerns on its profitability.
PASG Earnings
PASG Forecast & Estimates
13 analysts have analysed PASG and the average price target is 31.28 USD. This implies a price increase of 173.43% is expected in the next year compared to the current price of 11.44.
PASG Groups
Sector & Classification
PASG Financial Highlights
Over the last trailing twelve months PASG reported a non-GAAP Earnings per Share(EPS) of -14.35. The EPS increased by 32.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.09% | ||
| ROE | -242.72% | ||
| Debt/Equity | 0 |
PASG Ownership
PASG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.99 | 371.899B | ||
| AMGN | AMGEN INC | 15.18 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.76 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.61 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.17 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.09 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.87 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.62 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PASG
Company Profile
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 24 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Company Info
IPO: 2020-02-28
PASSAGE BIO INC
One Commerce Square, 2005 Market Street, 39Th Floor
PHILADELPHIA PENNSYLVANIA 19103 US
CEO: Bruce Goldsmith
Employees: 24
Phone: 12678660312
PASSAGE BIO INC / PASG FAQ
What does PASG do?
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 24 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Can you provide the latest stock price for PASSAGE BIO INC?
The current stock price of PASG is 11.44 USD. The price increased by 5.34% in the last trading session.
Does PASSAGE BIO INC pay dividends?
PASG does not pay a dividend.
How is the ChartMill rating for PASSAGE BIO INC?
PASG has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about PASSAGE BIO INC (PASG) stock?
13 analysts have analysed PASG and the average price target is 31.28 USD. This implies a price increase of 173.43% is expected in the next year compared to the current price of 11.44.
What is the Price/Earnings (PE) ratio of PASSAGE BIO INC (PASG)?
PASSAGE BIO INC (PASG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-14.35).
Can you provide the number of employees for PASSAGE BIO INC?
PASSAGE BIO INC (PASG) currently has 24 employees.